DE60303961D1 - Modifizierte saccharide, deren konjugate sowie deren herstellung - Google Patents

Modifizierte saccharide, deren konjugate sowie deren herstellung

Info

Publication number
DE60303961D1
DE60303961D1 DE60303961T DE60303961T DE60303961D1 DE 60303961 D1 DE60303961 D1 DE 60303961D1 DE 60303961 T DE60303961 T DE 60303961T DE 60303961 T DE60303961 T DE 60303961T DE 60303961 D1 DE60303961 D1 DE 60303961D1
Authority
DE
Germany
Prior art keywords
conjugates
linker
new
preparation
modified saccharides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303961T
Other languages
English (en)
Other versions
DE60303961T2 (de
Inventor
Aldo Giannozzi
Giovanni Averani
Francesco Norelli
Paolo Costantino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Chiron SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron SRL filed Critical Chiron SRL
Application granted granted Critical
Publication of DE60303961D1 publication Critical patent/DE60303961D1/de
Publication of DE60303961T2 publication Critical patent/DE60303961T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60303961T 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung Expired - Lifetime DE60303961T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0220198.6A GB0220198D0 (en) 2002-08-30 2002-08-30 Modified saccharides,conjugates thereof and their manufacture
GB0220198 2002-08-30
PCT/IB2003/004194 WO2004019992A1 (en) 2002-08-30 2003-09-01 Modified saccharides, conjugates thereof, and their manufacture

Publications (2)

Publication Number Publication Date
DE60303961D1 true DE60303961D1 (de) 2006-05-04
DE60303961T2 DE60303961T2 (de) 2006-10-26

Family

ID=9943241

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303961T Expired - Lifetime DE60303961T2 (de) 2002-08-30 2003-09-01 Modifizierte saccharide, deren konjugate sowie deren herstellung

Country Status (16)

Country Link
US (2) US8895516B2 (de)
EP (1) EP1534342B1 (de)
JP (2) JP5268222B2 (de)
CN (2) CN1688343B (de)
AT (1) ATE319481T1 (de)
AU (1) AU2003260921B2 (de)
BR (1) BR0314089A (de)
CA (1) CA2497167C (de)
DE (1) DE60303961T2 (de)
DK (1) DK1534342T3 (de)
ES (1) ES2260682T3 (de)
GB (1) GB0220198D0 (de)
MX (1) MXPA05002315A (de)
NZ (1) NZ538703A (de)
RU (2) RU2005108992A (de)
WO (1) WO2004019992A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
WO2004067030A2 (en) 2003-01-30 2004-08-12 Chiron Srl Injectable vaccines against multiple meningococcal serogroups
US20070258986A1 (en) * 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
ES2533248T3 (es) 2005-05-06 2015-04-08 Novartis Ag Inmunógenos para vacunas contra Meningitidis A
AR058592A1 (es) 2005-12-22 2008-02-13 Glaxosmithkline Biolog Sa Vacuna
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) * 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
AU2014200640B2 (en) * 2007-01-11 2016-06-16 Glaxosmithkline Biologicals Sa Modified saccharides
US9475864B2 (en) 2008-09-05 2016-10-25 University Of Massachusetts Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
EP3461496B1 (de) 2009-06-22 2023-08-23 Wyeth LLC Zusammensetzungen und verfahren zur herstellung von staphylococcus aureus serotyp-5 und 8-kapselpolysaccharid-konjugat-immunogenzusammensetzungen
PE20110023A1 (es) 2009-06-22 2011-01-31 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus
DK2493498T3 (en) * 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN102861326A (zh) * 2012-09-19 2013-01-09 天津康希诺生物技术有限公司 流脑多糖-蛋白质缀合疫苗及制备方法
EP2964665B1 (de) 2013-03-08 2018-08-01 Pfizer Inc Immunogene fusionspolypeptide
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
WO2017158480A1 (en) * 2016-03-15 2017-09-21 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Novel polysaccharide-protein conjugates and process to obtain thereof
MX2019002489A (es) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Vacuna contra neisseria meningitidis.
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
CA3050120A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
MX2020002557A (es) 2017-09-07 2020-07-13 Merck Sharp & Dohme Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2427341A1 (fr) * 1978-06-02 1979-12-28 Delalande Sa Nouveaux derives aminoglycosidiques hemisynthetiques, leur procede de preparation et leur application en therapeutique
ES2067854T3 (es) * 1990-03-15 1995-04-01 Tanabe Seiyaku Co Polisulfato de derivado de ciclodextrina y procedimiento para preparar el mismo.
CA2180149A1 (en) * 1993-12-28 1995-07-06 Michael Paul Deninno Steroidal glycosides
CA2189356A1 (en) * 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
CA2246760C (en) * 1997-01-21 2012-01-10 Pasteur Merieux Serums & Vaccins Polysaccharide-peptide-conjugates
WO1999007744A1 (en) * 1997-08-08 1999-02-18 Behringwerke Aktiengesellschaft Polysaccharide conjugates of biomolecules
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules
US5952454A (en) * 1997-12-12 1999-09-14 The United States Of America As Represented By The Department Of Health And Human Services Linking compounds useful for coupling carbohydrates to amine-containing carriers
MXPA04009339A (es) * 2002-03-26 2005-01-25 Chiron Srl Sacaridos modificados que tienen estabilidad mejorada en agua.
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture

Also Published As

Publication number Publication date
CN101863998A (zh) 2010-10-20
DE60303961T2 (de) 2006-10-26
BR0314089A (pt) 2005-11-16
MXPA05002315A (es) 2005-06-08
EP1534342A1 (de) 2005-06-01
CA2497167C (en) 2011-07-12
JP5268222B2 (ja) 2013-08-21
EP1534342B1 (de) 2006-03-08
DK1534342T3 (da) 2006-07-10
CA2497167A1 (en) 2004-03-11
CN101863998B (zh) 2012-08-29
RU2005108992A (ru) 2005-11-10
ES2260682T3 (es) 2006-11-01
JP2006511465A (ja) 2006-04-06
JP2012017342A (ja) 2012-01-26
US20150166593A1 (en) 2015-06-18
JP5314745B2 (ja) 2013-10-16
ATE319481T1 (de) 2006-03-15
CN1688343A (zh) 2005-10-26
RU2008150551A (ru) 2010-06-27
US20060263390A1 (en) 2006-11-23
GB0220198D0 (en) 2002-10-09
AU2003260921A1 (en) 2004-03-19
RU2531909C2 (ru) 2014-10-27
CN1688343B (zh) 2010-09-08
AU2003260921B2 (en) 2008-03-06
NZ538703A (en) 2006-09-29
US8895516B2 (en) 2014-11-25
WO2004019992A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
DE60303961D1 (de) Modifizierte saccharide, deren konjugate sowie deren herstellung
RU2412944C2 (ru) Иммуногены для вакцин против менингита а
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
MA30065B1 (fr) Vaccin
JP2005532287A5 (de)
MXPA03002779A (es) Derivados de glucopiranosiloxibencilbenceno y composiciones medicinales conteniendo los mismos.
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
PL410219A1 (pl) Kompozycja zawierająca koniugat leku obejmujący pochodne kalicheamycyny i przeciwciało, oraz kompozycja farmaceutyczna ją zawierająca
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
FR2805817B1 (fr) Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation
PT1254146E (pt) Processos de preparacao de polimeros de claritromicina e novo polimorfo iv
PT751144E (pt) Novos pro-farmacos antraciclinicos, metodo para preparacao e tambem a sua utilizacao em quimioterapia selectiva
ATE279943T1 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
GB0501964D0 (en) Chemical compounds
WO2011010084A8 (en) Cyclosporin conjugates
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
WO2004050711A3 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
DK1327146T3 (da) Forbindelse med et forgrenet linkermolekyle
WO2002042271A3 (en) Biphenylcarboxamides useful as lipid lowering agents
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
ATE308540T1 (de) Antithrombosemittel
WO2007050789A3 (en) Glycosyl-oligonucleotide conjugates and methods

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIEN, IT